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Dear Editor,
We are grateful for having the possibility to comment on
the BLetter to the editor^ regarding our article BBariatric
Surgery can Lead to Net Cost Savings to Health Care
Systems: Results from a Comprehensive European Decision
Analytic Model^.
Fildes et al. have compared our data and results with those
from the Swedish Obese Subjects study [1]. Our results are to
98 % based on gastric bypass surgery, the dominating proce-
dure in Sweden and in Europe. The SOS study comprises only
13 % gastric bypass patients, with the majority of patients
operated with purely restrictive operations, 68 % vertical
banded gastroplasty (VBG) and 19 % gastric banding. It has
been clearly shown that VBG is accompanied by high costs,
since up to 89 % of patients need a conversion [2]. In our
analysis, reduction of use of gastric bypass with correspond-
ing increase in other types of surgeries led to reduction of cost-
saving effect.
The comparison with the report by Weiner et al. [3] is not
quite appropriate either. That study has observed costs over a
6-year period for a group of bariatric surgery patients, most of
whom had had a gastric bypass, laparoscopic (38.3 %) or open
(35.4 %). However, the control group was chosen because
patients had diseases that were obesity-related. The study re-
ported a significant loss to follow-up over 6 years. Total costs
were higher in years 2 and 3 for the surgery group, but these
differences disappeared with time. Weiner et al. did not have
data beyond year 6. Since we report that the economic benefit
of surgery to health care system appears after 17 years, we
believe the results from the Weiner’s study do not contradict
our conclusion.
Limited duration of follow-up is an obvious and most com-
mon limitation of published empirical research of economic
consequences of bariatric surgery. Due to the initial high cost
of surgery, cumulative cost of surgical treatment has shown to
be higher compared with cumulative cost of alternative con-
servative management in a short- and mid-term time horizon.
To overcome this limitation and to incorporate long-term con-
sequence of treatments, we have employed lifetime horizon in
our model.
Fildes et al. had commented on omitting some of obesity-
related costs in our analysis, which can contribute to cost-
saving effect. We have considered the costs, related to surgery,
surgical complications, treatment of diabetes and cardiovas-
cular disorders. These costs constitute about 80 % of total
obesity-related cost as demonstrated in earlier [4–6] studies,
although was reported to be lower in more recent studies [7].
Swedish cost-of-illness studies in obesity have also focused
only on diabetes and cardiovascular outcomes [8]. In our opin-
ion, the most important costs are included into analysis.
Nevertheless, we agree that that with evolvement of treat-
ments (e.g. for cancer), the relative weight of these cost items
may be greater over the time.
We agree with the comment that validation of the model
with studies of bariatric surgery is of high value. In our anal-
ysis, incidence and remission of diabetes were validated with
the Scandinavian Obesity Surgery Registry, and the number of
cardiovascular outcomes and mortality was validated with the
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Action for Health in Diabetes (AHEAD) study of lifestyle
interventions, which included 5145 overweight or obese pa-
tients with type 2 diabetes (start BMI for validation was
35.9 kg/m2) [9]. It is acknowledged that there would always
be not enough validation attempts, as clinical data evolve over
time. We agree that additional specific validation exercises
would be of benefit.
In their comment, Fildes et al. focused on the overall con-
clusion from the analysis, although important sub-group dif-
ferences in economic outcomes were shown. Thus, cost-
saving effect was reported in the base-case analysis (with
characteristics of the cohort, mimicking characteristics of real
surgical candidates in Sweden) and single-cohort analysis of
diabetic patients and severe to super obese non-diabetic pa-
tients. But in single-cohort analysis, we did not observe cost
savings in patients with moderate and severe obesity and no
diabetes at baseline.
Bariatric surgery is a good example of a rapidly evolv-
ing area with changes of surgical techniques, dramatic
reduction in the use of open surgical approach and im-
proved safety. Empirical economic data, although being
the source of information of the greatest validity, are al-
ways available with delay, usually have limited follow-up
and often do not correspond to the current treatment prac-
tice. In this case, decision analytic modelling has an inev-
itable complementary role to inform clinical and policy
decision-making, acknowledging its simplification over
reality. Omitting data generated by comprehensive model-
ling would lead to underestimation of true economic value
of modern bariatric surgery.
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